Skip to Main Content
Try STAT+ TODAY
Trending:
Biotech
Coronavirus
First Opinion
Business
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

ASH winners and losers: Hemophilia therapies show promise, Syros stumbles

  • Adam Feuerstein

By Adam Feuerstein Dec. 11, 2017

Reprints
ASH 2017 story card
Hyacinth Empinado/STAT

ATLANTA — This weekend’s American Society of Hematology (ASH) annual meeting was bit like playing in a Brooklyn children’s soccer tournament: Everyone got a congratulatory trophy just for showing up.

Well … not everyone. To extend the tortured P.C. soccer metaphor, Syros Pharmaceuticals (SYRS) was ejected with a red card. Unsportsmanlike conduct.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Health insurers are painting a misleading picture of Medicare…
Health insurers are painting a misleading picture of Medicare Advantage savings, experts say
Biotech turns to new and strange viruses to overcome…
Biotech turns to new and strange viruses to overcome gene therapy’s limitations
Push to double up on Covid booster and flu…
Push to double up on Covid booster and flu shot may have a downside, experts caution
FDA: Ignore a pharma company’s deceptive racial equity argument…
FDA: Ignore a pharma company’s deceptive racial equity argument for keeping Makena, an ineffective preterm labor…
Biotech turns to new and strange viruses to overcome…
Biotech turns to new and strange viruses to overcome gene therapy’s limitations
Some European regulators are starting to take steps to…
Some European regulators are starting to take steps to ensure clinical trial results are reported

Recommended Stories